$INNOGEN-B(02591)$ is gearing

$INNOGEN-B (02591)$ is gearing up for a $100 million Hong Kong IPO to fuel its GLP-1 obesity drug development, diving headfirst into China's competitive weight-loss drug market. With their once-weekly injectable therapy, Diabegone, already approved for type 2 diabetes treatment in China and showing potential for weight reduction, Innogen's poised to take on established players like $Novo-Nordisk A/S(NVO)$ and $Eli Lilly(LLY)$ . This strategic move could be a game-changer for the company, offering a chance to tap into the growing demand for GLP-1-based treatments.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

Wade Shaw
08-12
Wade Shaw
GLP-1 market’s hot, but IPO timing feels frothy.
Meroy
08-11
Meroy
This IPO could really disrupt the market

Leave a comment

{"i18n":{"language":"en_US"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":465994169229496,"tweetId":"465994169229496","gmtCreate":1754774777703,"gmtModify":1754903860958,"author":{"id":4142551860919612,"idStr":"4142551860919612","authorId":4142551860919612,"authorIdStr":"4142551860919612","name":"nomadic_m","avatar":"https://community-static.tradeup.com/news/1f3661c844e575fec696ac41d1d30e18","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":12,"crmLevelSwitch":0,"currentWearingBadge":{"badgeId":"9427a906234c4b18a82ec3d7730b7fa8-1","templateUuid":"9427a906234c4b18a82ec3d7730b7fa8","name":"Star Contributor","description":"Published at least 3 PICK posts (or 10 IDEA posts) and, within the past 30 days, posted at least 1 PICK post (or 4 IDEA posts) and 1 comment","bigImgUrl":"https://community-static.tradeup.com/news/1866dcf97a73be1c330f85862546aedc","smallImgUrl":"https://community-static.tradeup.com/news/4f5c5fa8e2c7683bb5a7fce8753ee456","redirectLinkEnabled":1,"redirectLink":"https://ttm.financial/activity/market/2023/star-contributors/","hasAllocated":1,"isWearing":1,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2024.04.11","individualDisplayEnabled":0},"individualDisplayBadges":[],"fanSize":494,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"html":"<html><head></head><body><a href=\"https://ttm.financial/S/02591\"> $</a><a href=\"https://ttm.financial/S/02591\">INNOGEN-B</a><a href=\"https://ttm.financial/S/02591\">(02591)$ </a>is gearing up for a $100 million Hong Kong IPO to fuel its GLP-1 obesity drug development, diving headfirst into China's competitive weight-loss drug market. With their once-weekly injectable therapy, Diabegone, already approved for type 2 diabetes treatment in China and showing potential for weight reduction, Innogen's poised to take on established players like<a href=\"https://ttm.financial/S/NVO\"> $Novo-Nordisk A/S(NVO)$ </a>and<a href=\"https://ttm.financial/S/LLY\"> $Eli Lilly(LLY)$ </a>. This strategic move could be a game-changer for the company, offering a chance to tap into the growing demand for GLP-1-based treatments.</body></html>","htmlText":"<html><head></head><body><a href=\"https://ttm.financial/S/02591\"> $</a><a href=\"https://ttm.financial/S/02591\">INNOGEN-B</a><a href=\"https://ttm.financial/S/02591\">(02591)$ </a>is gearing up for a $100 million Hong Kong IPO to fuel its GLP-1 obesity drug development, diving headfirst into China's competitive weight-loss drug market. With their once-weekly injectable therapy, Diabegone, already approved for type 2 diabetes treatment in China and showing potential for weight reduction, Innogen's poised to take on established players like<a href=\"https://ttm.financial/S/NVO\"> $Novo-Nordisk A/S(NVO)$ </a>and<a href=\"https://ttm.financial/S/LLY\"> $Eli Lilly(LLY)$ </a>. This strategic move could be a game-changer for the company, offering a chance to tap into the growing demand for GLP-1-based treatments.</body></html>","text":"$INNOGEN-B(02591)$ is gearing up for a $100 million Hong Kong IPO to fuel its GLP-1 obesity drug development, diving headfirst into China's competitive weight-loss drug market. With their once-weekly injectable therapy, Diabegone, already approved for type 2 diabetes treatment in China and showing potential for weight reduction, Innogen's poised to take on established players like $Novo-Nordisk A/S(NVO)$ and $Eli Lilly(LLY)$ . This strategic move could be a game-changer for the company, offering a chance to tap into the growing demand for GLP-1-based treatments.","highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":2,"repostSize":4,"favoriteSize":0,"link":"https://ttm.financial/post/465994169229496","repostId":0,"isVote":1,"tweetType":1,"viewCount":1168,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":["02591","NVO","LLY"],"verified":2,"subType":0,"readableState":1,"langContent":"EN","currentLanguage":"EN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":true,"length":486,"optionInvolvedFlag":false,"xxTargetLangEnum":"ORIG"},"commentList":[{"id":466871585837152,"commentId":"466871585837152","gmtCreate":1755004946051,"gmtModify":1755005464137,"authorId":10000000000011036,"author":{"id":10000000000011036,"idStr":"10000000000011035","authorId":10000000000011036,"name":"Wade Shaw","avatar":"https://static.tigerbbs.com/a539edbf3388702a82cb1d4728704766","vip":8,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":465994169229496,"objectIdStr":"465994169229496","type":1,"supId":0,"supIdStr":"0","prevId":0,"prevIdStr":"0","content":"GLP-1 market’s hot, but IPO timing feels frothy.","text":"GLP-1 market’s hot, but IPO timing feels frothy.","html":"GLP-1 market’s hot, but IPO timing feels frothy.","likeSize":1,"commentSize":0,"subComments":[],"verified":10,"allocateAmount":0,"commentType":"valid","coins":0,"score":0,"disclaimerType":0},{"id":466509220061696,"commentId":"466509220061696","gmtCreate":1754904412967,"gmtModify":1755055741718,"authorId":9000000000000482,"author":{"id":9000000000000482,"idStr":"9000000000000482","authorId":9000000000000482,"name":"Meroy","avatar":"https://static.tigerbbs.com/724960a405e3f3639cbc483ae4560891","vip":8,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":465994169229496,"objectIdStr":"465994169229496","type":1,"supId":0,"supIdStr":"0","prevId":0,"prevIdStr":"0","content":"This IPO could really disrupt the market","text":"This IPO could really disrupt the market","html":"This IPO could really disrupt the market","likeSize":1,"commentSize":0,"subComments":[],"verified":10,"allocateAmount":0,"commentType":"valid","coins":0,"score":0,"disclaimerType":0}],"isCommentEnd":false,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/465994169229496"}